Dr. Clay B. Siegall: Healer, Scientist, Entrepreneur

To know Dr. Clay B. Siegall well is to know him as an entrepreneur and scientist. As a young adult, Clay Siegall watched his father’s cancer progress over a five-year period, until he died. From this point forward Siegall was trained as a scientist and dedicated himself to the study of genetics after receiving a Ph.D. from George Washington University. The futility of his father dying drove Siegall to improve the tools available to oncologists to treat cancer. Following receiving his Ph.D. Dr. Siegall worked with Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute and the National Institutes of Health. Dr. Siegall is a prolific researcher and has at least 70 publications and holds 15 patents.

 

Siegall, as genetics expert, combined with his pharmaceutical experience with Bristol-Myers, co-founded Seattle Genetics. He is its Chief Executive Officer and Chairman of the Board. Dr. Siegall’s primary goal was the development of targeted cancer therapies. Antibody Drug Conjugates (ADCs) have the cancer-killing ability to discriminate between healthy and diseased tissue. The use of ADC in the treatment of cancer is an example of a targeted cancer therapy.

 

Through Innovative scientific research, Seattle Genetics and its team of collaborating scientists developed an antibody-drug conjugate, marketed as ADCETRIS. ADCETRIS received FDA approval in 2011. With the collaboration of Takeda Pharmaceutical Company, ADCETRIS has been approved in more than 65 countries. ADCETRIS is the trade name for Brentuximab vedotin.

 

Dr. Siegall has fascinated the world of genetics, pharmaceuticals, and business. In 2013 Siegall received the University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences, and in 2012 he received the Pacific Northwest Ernst & Young Entrepreneur of the Year. Dr. Siegall has raised more than $330 million through public and private financing to support Seattle Genetics. Seattle Genetics, with collaboration agreements with MedImmune, CuraGen, Bayer, and Progenics has generated more than $65 million.

 

Dr. Clay B. Siegall moved past his sorrow when his father died. He vowed to spend his life finding a cure for cancer and honored his father by helping to cure others. His worked has not been completed.

 

Clay Siegall, Seattle Genetics, & Cancer Research

Living in this modern society gives us many more advantages especially when it comes to innovation. Every era has it’s own innovative products, services, and individuals, but the 21st Century has taken it to another level. Cancer research is no different and the fight against cancer has become a hot topic as of late thanks to Clay Siegall. This individual is one of the most well respected individuals in this exclusive industry. Siegall is known by many as a scientist, doctor, investor, and philanthropist. His resume is very accomplished as well as he is the holder of 15 patents, has written 70 publications, and he’s won the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year Award.

Dr. Siegall is the CEO and President of Seattle Genetics. This biotech giant specializes in the development and commercialization of cancer breakthrough therapies. These are some of the finest cancer fighting drugs in history and Seattle Genetics produces them in abundance. It’s flagship drug ADCETRIS has racked up more than $350 Million. Thanks to Dr. Siegall’s business savvy approach, ADCETRIS was entered into multiple strategic licensing deals with Pfizer, Genentech, and GlaxoSmithKline. With this merger, ADCETRIS is now available for use in up to 65 countries worldwide. This Bothell, Washington based company is on a roll as it’s stock has tripled in only a five year span. Seattle Genetics has many more drugs in it’s advanced pipeline for future reference. Another hiring blitz s to be expected in the coming years, which will add to it’s already 800+ man roster.

Of course all of this wouldn’t be possible without Dr. Siegall. His broad educational background and strong passion have made the company into a high profile name. He’s been here since it’s inception back in 1998 as well. The future appears to be much more brighter with Dr. Siegall on the scene and Seattle Genetics will continue to rewrite history through cancer research.

 

Innovative Medicine Keeps Healthy Cells Healthy During Cancer Treatment

Seattle Genetics is on a mission. The goal: to deliver chemotherapy only to damaged cells in cancer patients while sparing healthy cells and avoiding all of the unpleasant side effects of traditional cancer treatments. This top biopharmaceutical company is already helping cancer patients by way of Antibody-Drug Conjugates (ADCs), including their own ADCETRIS® (brentuximab vedotin). Headed by President, CEO and Chairman of the Board Clay Seigall, PH.D., Seattle Genetics pushes forward with research and drug trials involving this favorable approach to cancer treatment.

Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript
ADCs target specific proteins found on cancerous cells in the body. They are then absorbed by those cells and release the chemotherapy contained within, destroying only those cells. By saving healthy cells in the body, ADCs make treatment and recovery more bearable for the patient. This alternative to surgery, radiation, hormone treatments and traditional chemotherapy is already improving quality of life for many people.
Seattle Genetics takes pride in their work and for Dr. Seigall, it is personal. He has experienced first-hand the loss of a loved one to brain cancer when his father passed away during his second year of grad school. His curiosity at his father’s appointments landed him at George Washington University where he earned his PH.D. in genetics. This was after earning a B.S. in Zoology at the University of Maryland, working with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. He serves on the Board of Directors of Alder BioPharmaceuticals and Mirna Therapeutics, two private biotechnology companies, and UltraGenyx, a biopharmaceutical company. He is an author on more than 70 publications and holds 15 patents.
While ADCs are targeting certain proteins located on the outside of cells, future studies will include innovative biopharmaceuticals that have the ability to target the inside of cells and the immune system. Seattle Genetics has grown considerably since their start in 1998. Despite rapid growth, the company maintains an atmosphere of integrity and scientific excellence and clearly displays an unwavering passion for helping patients.

https://claysiegallblog.wordpress.com/

http://claysiegall.tumblr.com/